IMAC Holdings, operating as Ignite Proteomics, is a small early-stage clinical diagnostics company focused on protein-based cancer testing. The company pivoted in 2024 from orthopedic and regenerative medicine clinics to its current business after acquiring assets from Theralink Technologies. Its core product is the Ignite RPPA (Reverse Phase Protein Array) Assay, a lab-developed test that measures the activity of 32 protein markers in a cancer patient's tumor to help oncologists identify active drug targets and select targeted therapies. The company argues that protein-level analysis provides clinically actionable information that standard genomic testing misses, since most FDA-approved cancer drugs target proteins rather than genes. The currently available product is the Ignite RPPA Assay for Breast Cancer. Ignite Proteomics operates a CLIA-certified, CAP-accredited reference laboratory in Golden, Colorado, billing Medicare and private insurers on a per-test basis. Beyond clinical testing, the company holds exclusive licenses from Vanderbilt and George Mason University covering its core RPPA technology, which could support royalty-generating biopharma partnerships. Near-term growth priorities include securing broader insurance reimbursement, obtaining NCCN guideline endorsements, and expanding the test menu with a Pan-Tumor Assay covering additional cancer types expected in 2025 and 2026. The company has 15 employees and was delisted from Nasdaq in March 2025, with its stock now trading on the OTC Pink Market.